Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a two-acid cream fade stubborn melasma?

NCT ID NCT07727954

Disease control Sponsor: University of Guadalajara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a cream containing azelaic acid and tranexamic acid can reduce the dark patches of melasma better than a placebo. Adults with facial melasma will apply the cream daily for four weeks. Researchers will measure changes in pigmentation, quality of life, and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a topical cream containing 12% azelaic acid and 5% tranexamic acid
What this could lead to
If effective, this cream could offer a new, non-invasive option for reducing melasma pigmentation and improving quality of life.
What could go wrong
This is a small, short-term trial (40 people, 4 weeks). Results may not apply to all skin types, and the cream may cause skin irritation or not outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jun 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 60 years. * Clinical diagnosis of facial melasma. * Fitzpatrick skin phototypes II to V. * Willing and able to comply with all study procedures and scheduled visits. * Willing to use sunscreen throughout the study. * Provided written informed consent. Exclusion Criteria: * Pregnancy or breastfeeding. * Known hypersensitivity to azelaic acid, tranexamic acid, or any component of the study formulation. * Use of topical or systemic treatment for melasma within the previous 3 months. * Presence of facial skin diseases or active skin infections that could interfere with study assessments. * Participation in another clinical trial during the study period. * Any medical condition that, in the investigator's judgment, could interfere with study participation or evaluation of the outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperpigmentation Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma

Contacts and locations

Locations

  • The Skin Place

    Tijuana, Estado de Baja California, 22010, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.